Mach One’s Co-Development Plans (OTC:MNCN)

Mach One Corporation (OTC:MNCN) has announced that they have completed the first tranche of their investment in PanTheryx, Inc. as stipulated in the recent Letter of Understanding signed in August 2009. This action expedites development and introduction plans for an orally administered antibody therapeutic for treatment of pediatric diarrhea. The co-developed pediatric diarrhea product will initially be targeted for commercial introduction in India, where PanTheryx maintains a sales force and contract sales relationships. Both the companies are working on treatment of pediatric diarrhea as it is the second largest killer of children between age of birth to adolescence, with an estimated 1.4 million children dying each year from this illness.

Mach One Corporation is a global wellness company that provides biotechnology based solutions for positive, long term health and longevity benefits for humans and disease-threatened animals for commercial operations. On the other hand, PanTheryx Medical Pvt. Ltd. (a wholly owned subsidiary of PanTheryx, Inc.) is an emerging Indian company creating and selling healthcare products, including the acquisition, development, and commercialization of advanced technologies, for introduction into the Indian healthcare market. CEO of Mach One Corporation, Tad Ballantyne stated that the mutual goal for both the healthcare companies is to address this enormous health issue of pediatric diarrhea and through combined efforts they will be able to come out with new medical innovation.